Holen Sie sich die Stockscreener-App
3.00
16.28%
0.42
Clene Inc Aktie (CLNN) Neueste Nachrichten
CLNN stock touches 52-week low at $2.95 amid market challenges By Investing.com - Investing.com South Africa
CLNN stock touches 52-week low at $2.95 amid market challenges - Investing.com
Clene to Present at the Jones Healthcare and Technology Innovation Conference - The Manila Times
Clene Reveals Latest ALS and MS Treatment Innovations at Major Healthcare Conference - Stock Titan
Promising Nanotechnology Stocks To ResearchMarch 29th - MarketBeat
Roth Capital Has Negative Estimate for Clene Q1 Earnings - Defense World
Clene Inc. settles debt with equity issuance - Investing.com
Clene Inc.'S (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available For On-Demand Viewing - MENAFN.COM
Roth Capital Has Optimistic Outlook of Clene FY2027 Earnings - Defense World
Research Analysts Issue Forecasts for Clene Q1 Earnings - Defense World
What is HC Wainwright’s Estimate for Clene FY2028 Earnings? - Defense World
Clene stock touches 52-week low at $3.8 amid market challenges - Investing.com Australia
Clene stock touches 52-week low at $3.8 amid market challenges By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $31 target on Clene stock post-results By Investing.com - Investing.com Canada
Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025 - StreetInsider.com
H.C. Wainwright maintains $31 target on Clene stock post-results - Investing.com
Clene (NASDAQ:CLNN) Given “Buy” Rating at HC Wainwright - Defense World
Clene to Present at Jones Las Vegas Technology and Innovation Conference - citybuzz -
Clene’s (CLNN) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Clene Inc. Reports 2024 Financial Results and Strategic Plans - TipRanks
Clene Inc (CLNN) Reports Q4 EPS of -$5.67, Revenue of $0.36M, Mi - GuruFocus
Clene Inc. Files For Mixed Shelf Of Up To $160 MillionSEC Filing -March 24, 2025 at 04:51 pm EDT - MarketScreener
Clene (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data - The Globe and Mail
Clene Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights - The Manila Times
Breakthrough: Clene's ALS Treatment Shows 11.9-Month Survival Benefit in Severe Cases - Stock Titan
BiomednewsbreaksClene Inc. (NASDAQ: CLNN) Unveils Progress On CNM-Au8(R), Eyes Potential Fast-Track FDA Approval - MENAFN.COM
Bullish Clene Insiders Loaded Up On US$583.4k Of Stock - Yahoo Finance
Clene Inc. shareholder general resonance sells $12,091 in stock By Investing.com - Investing.com Australia
Clene Inc. shareholder general resonance sells $12,091 in stock - Investing.com
Dually-Listed Aerospace Stock Finds Premarket Success Following Key Announcement - The Globe and Mail
HC Wainwright Reaffirms “Buy” Rating for Clene (NASDAQ:CLNN) - Defense World
D. Boral Capital Reaffirms Buy Rating for Clene (NASDAQ:CLNN) - Defense World
H.C. Wainwright maintains Clene stock Buy rating, $31 target - Investing.com India
H.C. Wainwright maintains Clene stock Buy rating, $31 target By Investing.com - Investing.com South Africa
Clene reports ALS treatment survival benefit in trial By Investing.com - Investing.com Australia
Utah Biotech's Treatment Demonstrates Significant Survival Advantage for ALS Patients - streetwisereports.com
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Reports CNM-Au8 Significantly Improves Survival in ALS Patients - Financial Content
Clene Inc. (NASDAQ: CLNN) to Present CNM-Au8(R) Updates at 37th Annual Roth Conference - Financial Content
Clene reports ALS treatment survival benefit in trial - Investing.com India
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment - The Manila Times
Breakthrough: New ALS Drug Extends Patient Survival by 198 Days in Major Clinical Study - StockTitan
Clene (NASDAQ: CLNN) to Highlight Latest Achievements, Next Steps for CNM-Au8(R), at Q1 Virtual Investor Summit - Barchart
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Participate in 37th Annual Roth Conference - Financial Content
Clene to Present at the 37TH Annual Roth Conference - The Manila Times
Clene Inc. to Participate in 37th Annual Roth Conference with Virtual Fireside Chat and Investor Meetings - Nasdaq
Can Clene's Neurodegenerative Disease Treatments Transform ALS and MS Care? - StockTitan
Investornewsbreaks Clene Inc. (NASDAQ: CLNN) To Participate In 37Th Annual Roth Conference - MENAFN.COM
Clene (CLNN) to Release Quarterly Earnings on Wednesday - Defense World
Silicon Valley - Financial Content
Clene (NASDAQ: CLNN) CEO and CFO to Present at Investor Summit Virtual on March 11 - The Globe and Mail
New analyses in ALS planned to aid CNM-Au8’s accelerated approval - ALS News Today
What Will Clene Executives Reveal at the Upcoming Investor Summit? - StockTitan
Clene (NASDAQ:CLNN) Earns “Buy” Rating from HC Wainwright - Defense World
2.32%
1.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):